COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00354523
Recruitment Status : Terminated (Study closed following Phase I portion, insufficient activity to continue to Phase II.)
First Posted : July 20, 2006
Last Update Posted : December 17, 2014
Novartis Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:


Primary objectives:

To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors.

To determine the overall tumor response rate to imatinib mesylate in combination with capecitabine and dacarbazine as first line and second line therapy in advanced metastatic medullary thyroid carcinoma.

To determine the tolerability (toxicity) of this regimen.

Secondary objectives:

To determine the median overall survival (OS) and time to progression (TTP) for patients treated with this combination.

Condition or disease Intervention/treatment Phase
Solid Tumor Thyroid Cancer Drug: Capecitabine (Xeloda) Drug: DTIC-Dome (Dacarbazine) Drug: Gleevec (Imatinib Mesylate) Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Study Start Date : December 2004
Actual Primary Completion Date : November 2006
Actual Study Completion Date : August 2013

Arm Intervention/treatment
Experimental: Capecitabine + Dacarbazine + Imatinib
Capecitabine starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle. Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
Drug: Capecitabine (Xeloda)
Starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle.

Drug: DTIC-Dome (Dacarbazine)
Starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle.

Drug: Gleevec (Imatinib Mesylate)
Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
Other Name: Imatinib

Primary Outcome Measures :
  1. Maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine [ Time Frame: 21 day cycle ]
    The MTD is defined as the dose level below that producing dose limiting toxicity (DLT; i.e. any Grade 4 hematologic toxicity and /or non hematological toxicity >/= Grade 3 in 2/6 participants).

Secondary Outcome Measures :
  1. Objective Response Rate [ Time Frame: Minimally 9 weeks (overall study period 5 years) ]
    Objective response rate is defined to be the proportion of participants achieving Complete Response (CR) or Partial Response (PR). Response to treatment will be measured using the RECIST criteria with radiological evaluation every 9 weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age greater than 16 years old.
  2. Signed informed consent.
  3. During the phase I portion of the trial, any patient with a proven solid tumor for which no curative or standard treatment is available is eligible. However, for the phase II portion of the trial, patients are required to have medullary thyroid carcinoma that is unresectable or metastatic.
  4. For the phase I portion of the protocol, there is no limit to the amount of prior therapy participants may have received. For the phase II portion of the trial, 0-1 prior regimens are allowed.
  5. ECOG performance status must be 0-2.
  6. Adequate hepatic, renal, and bone marrow function: Absolute neutrophil count greater than/equal to 1,500/uL; platelets greater than/equal to 100,000/uL; total bilirubin less than/equal to 1.5 X institution upper limits of normal (ULN); AST (SGOT)/ALT (SGPT) less than/equal to 2.5 X institutional ULN; Creatinine less than/equal to 1.5 mg/dL
  7. Female patients of childbearing potential must have a negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  8. Patients may have received prior radiation treatment but the last fraction of radiation treatment must have been completed at least 4 weeks prior to entry on this study.
  9. Patients may have been treated with surgery but the surgical intervention must have been done at least 3 weeks prior to entry on this study.
  10. In the phase I part of the trial, measurable disease is not required. Radiographic and measurable evidence of disease is required for the phase II part of the trial. To be considered evaluable for complete or partial response, patients must have at least one measurable lesion as per the modified RECIST Criteria. If radiation was previously received, measurable disease must occur outside the previous radiation field, unless disease progression has been documented.
  11. Both men and women and members of all ethnic groups are eligible for this trial.

Exclusion Criteria:

  1. In previously treated patients, patients should not have received prior dacarbazine, imatinib mesylate, 5-fluorouracil, or capecitabine. This requirement does not apply to the phase I patients.
  2. Uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias not well controlled with medication, myocardial infarction within the previous 6 months, or psychiatric illness/social situations that would limit compliance with study requirements.
  3. Patients who have had chemotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 28 days earlier.
  4. Patients may not be receiving any other investigational agents, or have participated in any investigational drug study within 28 days preceding start of study treatment.
  5. The teratogenic potential of this combination is currently unknown. Women who are pregnant or lactating are excluded.
  6. History of any other malignancy in the last 5 years, except that patients with a prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with treated disease processes believed to be associated with MEN2, such as pheochromocytomas and primary hyperparathyroidism are allowed in the study.
  7. Concomitant use of warfarin is not allowed. Low molecular weight and standard heparin use is allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00354523

Layout table for location information
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Novartis Pharmaceuticals
Layout table for investigator information
Principal Investigator: James Yao, MD M.D. Anderson Cancer Center
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00354523    
Other Study ID Numbers: 2004-0475
First Posted: July 20, 2006    Key Record Dates
Last Update Posted: December 17, 2014
Last Verified: December 2014
Keywords provided by M.D. Anderson Cancer Center:
Solid Tumor
Thyroid Cancer
Medullary Thyroid Cancer
Advanced Metastatic Medullary Thyroid Carcinoma
Imatinib Mesylate
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Imatinib Mesylate
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents